Skip to main content

IBA Notice of Full Year 2020 Results and Conference Call

Written by Customer Service on . Posted in Public Companies.

FY20 Results Conference Call to take place on Thursday, 25 March 2021 at 3pm CETLouvain-la-Neuve, Belgium, 2 March 2021 – IBA (Ion Beam Applications S.A., EURONEXT), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces today that it will publish its consolidated results for the full year 2020 on Thursday, 25 March 2021 at 7am CET.Conference Call InformationIn addition to the press release, Olivier Legrain, Chief Executive Officer, and Soumya Chandramouli, Chief Financial Officer, will host a conference call and webcast, conducted in English, to present the full year results, followed by a Q&A session.This conference call will be held on Thursday, 25 March 2021 at 3pm CET / 2pm GMT / 10am EDT / 7am PDT and can be accessed online at:
http://arkadinemea-events.adobeconnect.com/iba250321/event/registration.html If you would like to participate in the Q&A, please dial (PIN code 24698548#):Belgium:                     +32 2 403 58 16
UK:                             +44 20 71 94 37 59
NL:                              +31 207 09 51 19
LU:                              +352 2 730 01 63
US:                             +1 64 67 22 49 16
FR:                              +33 1 72 72 74 03The presentation will be available on IBA’s investor relations website and on:
https://iba-worldwide.com/content/iba-full-year-2020-results-web-conference  shortly before the call.To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled webcast.About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has the largest number of installed proton therapy systems across the world.IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).More information can be found at www.iba-worldwide.comFor further information, please contact:IBA
Corporate Communication
+32 10 47 58 90
communication@iba-group.comFor media and investor enquiries:Consilium Strategic Communications
Amber Fennell, Angela Gray, Lizzie Seeley
+44 (0) 20 3709 5700
IBA@consilium-comms.comAttachment210302-FYR2020_Conf-call-announcement_EN

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.